PCO371 is a nonpeptidyl, orally active agonist of Parathyroid hormone type 1 receptor (PTHR1). It stimulates cAMP production in COS-7 cells with an EC50 of 2.4 μmol/L. It also acts as an osteoporosis drug and significantly enhances bone mineral density (BMD) and bone strength in the lumbar vertebrae of osteopenic ovariectomized (OVX) rats. It also […]

LY3522348 is a highly selective oral dual inhibitor of the human ketohexokinase isoforms C and A, with IC50 values of 20nM for hKHK-C and 24nM for hKHK-A. It shows a significant pharmacodynamic effect in a mouse model of fructose metabolism.

LY3522348 is a highly selective oral dual inhibitor of the human ketohexokinase isoforms C and A, with IC50 values of 20nM for hKHK-C and 24nM for hKHK-A. It shows a significant pharmacodynamic effect in a mouse model of fructose metabolism.

LY3522348 is a highly selective oral dual inhibitor of the human ketohexokinase isoforms C and A, with IC50 values of 20nM for hKHK-C and 24nM for hKHK-A. It shows a significant pharmacodynamic effect in a mouse model of fructose metabolism.

LY3522348 is a highly selective oral dual inhibitor of the human ketohexokinase isoforms C and A, with IC50 values of 20nM for hKHK-C and 24nM for hKHK-A. It shows a significant pharmacodynamic effect in a mouse model of fructose metabolism.

HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.

HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.

HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.

HC-258 is a covalent acrylamide inhibitor of TEAD that reduces the CTGF, CYR61, AXL, and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells.

THZ1 is a potent and covalent inhibitor of CDK7 with an IC50 of 3.2 nM. It also inhibits the CDK12 and CDK13 and downregulates MYC expression. It exhibits strong anti proliferative effect across a broad range of cancer cell lines including human T-cell acute lymphoblastic leukaemia (T-ALL) cancer.